Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

Cancer - 15 Feb 2012

Kriege Mieke, Jager Agnes, Hooning Maartje J, Huijskens Elisabeth, Blom Jannet, van Deurzen Carolien H M, Bontenbal Marijke, Collee J Margriet, Menke-Pluijmers Marian B E, Martens John W M, Seynaeve Caroline

Abstract excerpt

BACKGROUND: We assessed the efficacy of taxane chemotherapy in BRCA1- and BRCA2-associated patients compared with sporadic metastatic breast cancer patients. METHODS: Response rates (RRs) to and progression-free survival (PFS) after taxane chemotherapy of 35 BRCA1-associated and 13 BRCA2-associated metastatic breast cancer patients were compared with those outcomes in 95 matched (1:2) sporadic patients. Matching...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged-Ring Compounds

Share to Disease-Free Survival

Share to Pharmacogenetics

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Taxoids

Source

Identifiers

PMID: 21761396
DOI: 10.1002/cncr.26351

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.PMID 21761396Read ↗

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Systemic therapy options in BRCA mutation-associated breast cancer.Semantic proximity Read ↗

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.Semantic proximity Read ↗

Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Semantic proximity Read ↗

[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].Semantic proximity Read ↗

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.Semantic proximity Read ↗

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.Semantic proximity Read ↗

Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approachSemantic proximity Read ↗

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.Semantic proximity Read ↗

BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxaneSemantic proximity Read ↗

Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.